Dapagliflozin Lowers Blood Pressure in Salt-Sensitive Hypertension Independently of Renal Inflammation in Dahl-SS Rats
Background
Salt-sensitive hypertension is a progressive and complex condition characterized by early albuminuria, subsequent renal injury, and chronic inflammation, yet its initiating mechanisms remain poorly understood. Current therapeutic strategies often target downstream effects, leaving a gap in addressing the early drivers of the disease. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, like dapagliflozin, are known for their renoprotective effects in conditions like diabetic kidney disease (DKD), often linked to metabolic improvements and inflammation reduction. This study investigates if SGLT2 inhibition could intervene early in salt-sensitive hypertension, specifically exploring its impact on proximal tubule function and inflammation.
Study Design
Researchers investigated early salt-sensitive hypertension in male Dahl salt-sensitive (SS) rats fed a 4.0% NaCl high-salt (HS) diet for 7 days. They assessed blood pressure, renal injury, and inflammation. In parallel, a proximal tubule cell line was exposed to albumin to test for cytokine release, and the effect of dapagliflozin cotreatment was evaluated. Finally, the study examined whether dapagliflozin modified the response to the 7-day HS diet in SS rats, focusing on blood pressure and renal macrophage accumulation. Key assays included urinary albumin and CCL2 measurements, alongside macrophage accumulation assessment.
Results
In Dahl-SS rats fed a 4.0% NaCl high-salt (HS) diet, urinary albumin and CCL2 levels were higher compared to control salt-fed rats, preceding any significant differences in blood pressure. After 7 days on the HS diet, renal macrophage accumulation was also higher in HS-fed SS rats and correlated positively with albuminuria. In vitro, albumin exposure induced CCL2 release from cultured proximal tubule cells, a response that was prevented by dapagliflozin cotreatment. However, in the in vivo SS rat model:
Dapagliflozin blunted the development of salt-induced hypertension, but notably, it didn't reduce renal macrophage accumulation. This indicates a dissociation between the blood pressure-lowering effect of SGLT2 inhibition and its impact on renal inflammation in this early phase of salt-sensitive hypertension.
Key Findings
- Urinary albumin and
CCL2were higher in Dahl-SS rats on a high-salt diet before blood pressure elevation. - Renal macrophage accumulation was higher in high-salt fed SS rats and correlated positively with albuminuria.
- Albumin induced
CCL2release from proximal tubule cells, which dapagliflozin cotreatment prevented. - Dapagliflozin blunted the development of salt-induced hypertension in SS rats.
- Dapagliflozin did not reduce renal macrophage accumulation, suggesting an inflammation-independent effect on blood pressure.
Why It Matters
This research suggests that SGLT2 inhibition with dapagliflozin offers a novel, inflammation-independent strategy for early blood pressure management in salt-sensitive hypertension. While SGLT2 inhibitors are well-established for their benefits in diabetes and heart failure, this study expands their potential utility to a specific hypertensive phenotype, even in the absence of overt inflammation reduction. For clinicians and biohackers, this implies that SGLT2 inhibitors might be considered earlier or in different contexts for blood pressure control, particularly where salt sensitivity is a factor. The finding that blood pressure reduction occurred without a decrease in renal macrophage accumulation highlights a distinct mechanism, potentially involving direct effects on sodium handling or vascular tone rather than solely anti-inflammatory pathways. Further research is needed to translate this 7-day rat model finding into human protocols, but it opens avenues for exploring SGLT2 inhibitors in primary hypertension prevention or early intervention.
dapagliflozin
salt-sensitive-hypertension
sglt2-inhibition
albuminuria
renal-inflammation
blood-pressure